Why Us
Key Differentiators
Therapeutic Competencies
Our Clients
Our Team
Solutions
Pricing and Contracting Strategies
Patient Support Services
Payer Marketing and Value Propositions
Innovative Contracting
Rare and Orphan Therapy Insights
Market Access Organizational Development
Advisory & Market Research
Platforms
RE Assist
News and Events
Social Media
Press Releases
Conferences
Contact Us
Home
>
On rare drugs, is ICER at least partly right?
News
Reset
<
>
April 15, 2022
On rare drugs, is ICER at least partly right?
By Roger Longman & Ellen Licking
LOADING
LOADING
